MinorDirect oral anticoagulants (factor Xa inhibitors)×Allylamine antifungal (systemic and topical)
Updated · Methodology
Mechanism
Rivaroxaban is metabolised in the liver by CYP3A4, CYP2J2 and CYP-independent pathways, and part of the dose is excreted unchanged by the kidneys. Its elimination also depends on the transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) (rivaroxaban SmPC, European Medicines Agency, EMA). Rivaroxaban levels rise markedly with strong inhibitors of both CYP3A4 and P-gp, such as the azole antifungals ketoconazole, itraconazole, voriconazole and posaconazole (rivaroxaban SmPC, EMA). Terbinafine is an antifungal of another class, an allylamine. Of the cytochrome P450 enzymes, it markedly inhibits only CYP2D6. It has a negligible effect on the clearance of drugs metabolised by other P450 enzymes and does not change the clearance of digoxin, a P-gp substrate (terbinafine SmPC; terbinafine label, US Food and Drug Administration, FDA). Rivaroxaban is not metabolised by CYP2D6, and terbinafine is not among the antifungals in the table of the 2021 European Heart Rhythm Association (EHRA) practical guide.
Symptoms
The documents describe no symptoms linked to this combination. The main risk of rivaroxaban is bleeding, most often from mucosa: nosebleeds and gum, gastrointestinal and genitourinary bleeding, and anaemia (rivaroxaban SmPC, European Medicines Agency, EMA). Terbinafine rarely damages the liver, sometimes to the point of severe liver failure. Signs include persistent unexplained nausea, loss of appetite, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine or pale stools (terbinafine SmPC). Very rarely terbinafine lowers platelet and neutrophil counts, and thrombotic thrombocytopenic purpura has been reported (terbinafine SmPC).
Management
According to the documents, the combination is acceptable, and the doses of rivaroxaban and terbinafine need no change. Terbinafine is not one of the strong inhibitors of CYP3A4 and P-glycoprotein with which rivaroxaban is not recommended (rivaroxaban SmPC, European Medicines Agency, EMA; Xarelto label, US Food and Drug Administration, FDA). Check liver function before prescribing terbinafine, repeat the tests after 4–6 weeks of treatment and stop terbinafine at once if liver tests rise (terbinafine SmPC). Rivaroxaban is contraindicated in liver disease with coagulopathy and a clinically relevant bleeding risk (rivaroxaban SmPC, EMA). Unexplained thrombocytopenia or anaemia needs investigation. If thrombotic thrombocytopenic purpura is suspected, interrupt terbinafine at once, and stop it if the diagnosis is confirmed (terbinafine SmPC; terbinafine label, FDA). Renal function matters for both: terbinafine is not recommended with creatinine clearance below 50 mL/min, rivaroxaban is used with caution at 15–29 mL/min and is not recommended below 15 mL/min (terbinafine SmPC; rivaroxaban SmPC, EMA). During rivaroxaban treatment, watch for signs of bleeding and interrupt rivaroxaban if severe bleeding occurs (rivaroxaban SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Xarelto (rivaroxabán) – ficha técnica en CIMA (2026)– AEMPS CIMA, Xarelto 20 mg comprimidos recubiertos con película, nº registro 08472018 (EU/1/08/472), secciones 4.3, 4.4 y 4.5
- FDA: Xarelto (rivaroxaban) prescribing information (2026)– FDA label, DailyMed setid 10db92f9-2300-4a80-836b-673e1ae91610, version 65, revised 09/2026, sections 5.2 and 7
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6
- AEMPS: Ficha técnica: Terbinafina, Terbinafina Normon 250 mg comprimidos (nº registro 68185), sección 4.4 (2026)– AEMPS, CIMA, nº registro 68185 (Terbinafina Normon 250 mg comprimidos EFG, Laboratorios Normon), revisión 10/2026, secciones 4.4 y 4.5
- FDA: Terbinafine tablets, Cipla (terbinafine) prescribing information (2025)– FDA, DailyMed setid 18b16aad-1877-4b07-b532-f0ef4843af91 (Cipla USA), versión 6, efectiva 09/2025, secciones 7 y 12.3